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Objectives: To build an Excel calculator, including demographic and clinical char-
acteristics of Ankylosing Spondylitis (AS) patients, and estimate annual health 
care costs of AS patients in Turkey. MethOds: The study data was obtained from 
the Turkish national health insurance database, MEDULA (2009-2011). Adult AS 
patients (ages 18-99) were identified for the identification period (June 1, 2010 - 
December 31, 2010) through the use of International Classification of Disease Tenth 
Revision Clinical Modification (ICD-10-CM) codes. Patients were required to have 
two AS diagnoses at least 60 days apart, with at least 1 year of continuous health 
plan enrollment for the baseline and follow-up years. Patients were grouped as 
prevalent and incident cases, and generalized linear models (GLMs) were used to 
estimate risk-adjusted total annual costs for prevalent and incident cases. The 
expected annual cost value was based on patient demographic and clinical char-
acteristics. Coefficients of patients’ demographic and clinical characteristics were 
built in the Excel calculator. Using the calculation, a marginal effects table was 
created after GLM estimation. Results: A total of 2986 patients met all inclusion 
criteria (603 incident; 2383 prevalent patients). Demographic and clinical char-
acteristics of the patients were entered into the Excel calculator. Risk-adjusted 
annual total costs were calculated as € 3307 for prevalent cases and € 2000 for 
incident cases. Prior biologic use significantly contributed to total medical costs 
for both prevalent and incident AS patients (p< 0.001). For incidence cases, the cost 
of care was lower for the 18-39 age group when controlling for other factors. For 
prevalent cases, there were no differences in health care costs in terms of region, 
gender, age, comorbidities, or prior non-steroidal anti-inflammatory drug (NSAID) 
or disease-modifying anti-rheumatic drug (DMARD) use. cOnclusiOns: An Excel 
calculator is an important tool to estimate and compare AS-related health care 
costs in outcomes research.
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Objectives: To derive a claims-based severity index for rheumatoid arthritis 
(SIFRA) and examine its impact on prevalent rheumatoid arthritis (RA) patients in 
Turkey. MethOds: Using the Turkish national health insurance database MEDULA 
(01JUN2009-31DEC2011), prevalent RA patients were identified. Patients were 
required to be age 18-99, have two RA diagnoses ≥ 60 days apart and be continu-
ously enrolled 1 year pre- (baseline period) and post-index date (follow-up), which 
was the first RA claim during the identification period (01JUN2010-31DEC2010). The 
SIFRA score was derived for each patient. RA-related indicators were sub-grouped as 
clinical and functional status, extra-articular manifestations, surgical history and 
medications. The strength of each relationship was measured from 0= no relation-
ship to 6= perfect relationship, and assessed by six board-certified, clinically active 
rheumatologists according to the Delphi panel method. The index was previously 
validated and applied to the U.S. Department of Veteran Affairs, Veterans Health 
Administration (VHA) data. Results: For the total of 1,920 identified RA patients, 
SIFRA scores ranged between 0 and 69.40, with a mean value of 14.21, and a standard 
deviation (SD) of 10.26. Mean SIFRA scores were 7.05 (49.57%), which consisted of 
clinical and functional status variables, followed by 6.32 (44.47%) for medications, 
0.48 (3.40%) for radiology and laboratory findings, 0.32 (2.25%) for extra-articular 
manifestations (pulmonary nodules, subcutaneous nodules, vasculitis ever, Felty’s 
syndrome ever), and 0.04 (0.31%) for surgical history (cervical spine fusion, hand/
foot joint replacement, foot joint/ankle/wrist fusion, total hip/knee/elbow/shoulder 
replacement). cOnclusiOns: SIFRA demonstrated evidence of being a significant 
determinant for health care costs and biologic therapy use. This study suggests 
that SIFRA could be an important methodological tool to control for severity in 
RA-related outcomes research. Any comparative effectiveness studies in RA treat-
ment should include severity scores in the analysis.
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Objectives: Clinical oncology research projects require participation of oncolo-
gists and/or hematologists to recruit patients and/or assess clinical outcomes. A 
variety of methods is used to recruit office or hospital based physicans. Specifically 
for studies with an epidemiological aspect, the study should not rely on the typi-
cal clinical expert sites, thus, alternative recruitment pathways are increasingly 
considered. The objective of our study was thus to assess the benefits of using 
physician panels for site recruitment. MethOds: In 2012, a representative survey 
among members of a managed physician panel (All Global’s managed panel of 
oncologists and hematologists in US, UK, GER, FR, IT and SP) was conducted. A 
Sample of oncologists and hematologists was selected. The panel was stratified by 
country and within the strata physicians were randomly selected. 335 out of 1.303 
oncologists and hematologists in the sample (25,7%) reported about their former 
experience with clinical trials and post-approval studies, their willingness to par-
ticipate in future studies and their adherence to aspects of GCP rules. Results: A 
total of 284 (84,7%) of the physicians have formerly participated in clinical trials and 
276 (67,2%) in post-approval studies. A total of 88,9% of the experienced oncologists 
and hematologists were willing to participate in future studies. More than 80% of 
this group was ready to be named as principal investigator to an ethical commit-
tee, to report serious adverse events to the sponsor of the study and to ask patients 
for written informed consent. No substantial difference between countries was 
detected. cOnclusiOns: Since no special incentive was offered for participation 
the response rate was satisfactory Managed oncologist panels are a cost-effective, 
odds model has a natural interpretation of the treatment effect, is flexible in terms of 
handling data with different numbers of categories, but relies on the proportional odds 
assumption. The ordered logistic model also has a natural interpretation of the treat-
ment effect, but increases in complexity when handling data with a large number of 
categories. The multinomial model’s interpretation for the treatment effect is difficult, 
but it can model a large number of categories and can handle unordered competing 
risks and time dependent data. cOnclusiOns: There are three methods for incor-
porating multinomial data in a meta-analysis framework with various advantages 
and disadvantages. Selection of the appropriate model appears to be most dependent 
on the characteristics of the dataset. We determine that there is sufficient cause for 
future research focusing on a quantitative comparison of these different methods.
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Objectives: While multiple treatment comparisons (MTC) generally provide strong 
evidence, many are accompanied with uncertainty that makes life challenging for 
decison makers. Seeking reduction in uncertainty from non-comparative trial can ease 
decision-making, but the validity of this approach must be tested. Using an example of 
treatments for cryptococcal meningitis (CM), our objective was to assess the value and 
validity of incorporating non-comparative trial evidence via prior distributions in the 
Bayesian MTC framework. MethOds: We conducted a Bayesian MTC meta-analysis 
with and without informative priors and reported odds ratios (OR) with 95% credible 
intervals (CrI). Non-comparative data were incorporated in a two-stage approach. First 
meta-analysis for proportions was used to pool all relevant non-comparative outcomes 
for each treatment. Second, these results were used to construct informative priors for 
the comparative treatment effect parameters (the log odds ratios) in the Bayesian MTC. 
Treatments considered were amphotericin (AmB)-based therapy coupled with either 
flucytosine (5FC) or fluconazole (Azole). Results: Twenty-seven studies (N= 1,938), 15 
head-to-head drug comparison trials and 12 studies evaluating a single drug, described 
early mortality. Twenty-nine studies, 17 head-to-head and 12 single-arm studies, 
described late mortality. Incorporating non-comparative trials via informative priors 
improved the precision of several comparisons. For early mortality for example, the 
OR for AmB+Azole vs AmB+5FC was 0.26 (95%CrI 0.04-1.26) with a conventional MTC, 
and 0.24 (0.04-0.98) with informative priors. Use of informative priors reduced the DIC 
by 38% and the heterogeneity by 28%, indicating a better model fit. Moreover, evidence 
from the non-comparative studies was coherent with the randomized evidence, add-
ing to the validity of the approach. cOnclusiOns: Incorporating non-comparative 
studies as informative priors in Bayesian MTCs appears a viable approach for reducing 
the uncertainty in MTCs, and thus easing decision making.
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Objectives: Understanding the impact of caring for a person with schizophrenia 
on caregivers’ lives and emotional and physical well-being is of increasing interest 
for health care decison makers. The Zarit Burden Interview (ZBI) is an established 
measure of caregiver impact for Alzheimer’s disease. Face and content validity 
of the ZBI have not yet been established in schizophrenia and were explored in 
this study based on qualitative insights from caregivers of people with schizo-
phrenia. MethOds: A targeted literature review and consideration of best practice 
guidelines for development of self-report questionnaires informed initial ZBI modi-
fications. Face and content validity of the newly labelled Schizophrenia Caregiver 
Questionnaire (SCQ) were assessed via comprehensive semi-structured interviews 
with a diverse range of 19 US caregivers of people with schizophrenia. Interviews 
were initially open-ended and explored caregivers’ experience of caring for a per-
son with schizophrenia (concept elicitation). Cognitive debriefing of the draft SCQ 
then assessed relevance and understanding. Results: Initial review of the ZBI 
informed changes to item wording, recall period, and response scales to improve 
face validity. The qualitative literature review and concept elicitation interviews 
informed ten additional items assessing concepts important to caregivers, not 
included in the ZBI: tiredness, stress, disturbed sleep, sadness, medication admin-
istration issues, worries about future episodes, worsening symptoms, frustration, 
emotional highs and lows, and impact on work. Following cognitive debriefing inter-
views, five items were modified to improve relevance and understanding; otherwise, 
caregiver feedback supported the content validity and comprehensiveness of the 
resulting SCQ. cOnclusiOns: SCQ demonstrated good face and content validity 
for the assessment of caregiver impact in schizophrenia and is a promising tool for 
communication of caregiver outcomes to health care decision makers. Tiredness, 
disturbed sleep and sadness are included in depression scales hence there may be 
overlap if depression is assessed). Further work determining final SCQ content/
scoring and psychometric properties is ongoing.
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